Pharmaceutical Contract Manufacturing Market 2018: New Investment Opportunities Emerge to Widen Segments in Healthcare Industry by 2023

Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Pharmaceutical Contract Manufacturing Market Research Report- Global Forecast till 2023” Gives industry size, top players and worldwide demand

Market Scenario

The pharmaceutical industry is experiencing a dramatic change. Pipeline challenges, pricing pressures, and emerging global markets are redesigning the way these companies operate. Providers to the pharmaceutical industry, such as contract manufacturers, will need to alter as well. In the year to come, contract manufacturers that distinguish their offerings and abilities will be able to retain customers and grow their business within this highly competitive marketplace. Those that are able to adapt quickly, by taking benefit of the transformative nature of the industry, will position themselves as market leaders.

Furthermore, in the near future, various pharmaceutical contract manufacturing organizations will reflect on prospects to provide services and support further “upstream” in the drug development process. With rigorous margin pressures on the core business of commercial manufacturing and packaging, some PCM are offsetting costs by offering more project-based consulting and development activities. Moreover, in some cases where this has clearly worked for some of the superior pharmaceutical contract manufacturers, altering them to what industry calls contract development and manufacturing organizations (CDMO), many companies have reduced their entry into this market by overleveraging their current offerings.

View Reports Sample @


Further, the increased number of abroad pharmaceutical contract manufacturing alternatives has left contract manufacturers hostile to conserve profit margins and distinguish themselves in an already competitive marketplace. The market has become progressively driven by price rather than value, making it mandatory upon pharmaceutical contract manufacturers to provide value outside of the traditional commercial manufacturing phase of the drug product lifecycle.

Another reason for increasing prospect in pharmaceutical contract development services is found in the growth of developing biotech’s. Most of these companies are heavily dedicated to the development of drug compounds to address a specific therapeutic area. The companies lack infrastructure in the areas of formulation, clinical and regulatory agency submission. Frequently, the desired end state for these companies is to sell to a big pharma or a biotech company. However, if the suitable level of funding exists, partnership with a pharmaceutical contract manufacturer can provide another viable option. By working together, an emergent biotech company, an established donor company, and a pharmaceutical contract manufacturer can move a product through approvals stages and into the global markets.

The global Pharmaceutical Contract Manufacturing market is expected to grow at a CAGR of 7.2% during the forecast period 2017-2023. 

Intended Audience

  • Medical Devices Companies
  • Hospitals & Clinics
  • Research and Development (R&D) Companies
  • Government Research Institute
  • Academic Institutes and Universities 


The global Pharmaceutical Contract Manufacturing market is segmented on the basis of type,

On the basis of type, the market is classified into Active Pharmaceutical Ingredient (API) Manufacturing, Finished Dosage Formulation (FDF) Market.

Key Findings

  • The global Pharmaceutical Contract Manufacturing market is expected to reach USD 107,004.0 million by 2023 at a CAGR of 7.2%.
  • On the basis of types, Active Pharmaceutical Ingredient (API) Manufacturing segment is expected to command the largest market share of 7% over the review period and Finished Dosage Formulation (FDF) Secondary Market is expected to grow at the fastest CAGR of 6.5% during the forecast period 2017-2023
  • The Americas hold the largest share of the Pharmaceutical Contract Manufacturing market and is expected to reach USD 40,041.5 million by 2023
  • Asia Pacific is the fastest growing market, which is expected to grow at a CAGR of 7.7% over the 2017-2023
  • Low tech pharmaceutical contract manufacturing manufacture is shifting to the developing world especially China and India. The developed regions must accommodate this shift by shifting to high tech segment of the pharmaceutical contract manufacturing market such as biologics.
  • China has feverously increased its capacity for API manufacturing while India is a better destination for formulation development and manufacturing.


Report with Discount Available  @

Key Players

Some of key the players in the market are Catalant, Boehringer Ingelheim, Lonza AG, Grifols International, S.A, AbbVie Inc, Patheon Inc., Vetter, Pharmaceutical Product Development and others. 




2.1 Scope Of The Study 13

2.1.1 Research Objective 13

2.1.2 Assumptions 13

2.1.3 Limitations 14


3.1 Research Process 15

3.2 Primary Research 16

3.3 Secondary Research 16

3.4 Market Size Estimation 16


4.1 Drivers 19

4.1.1 Patent Protection Expiration Of Major Drugs And Growing Demand For Generic Drugs Will Boost The Growth Of CMOs Globally (Impact Weightage 40%) 19

4.1.2 Competition And Economics Of Production And Trade To Favour CRO (Impact Weightage – 25%) 20

4.1.3 Mutual Benefit To Both Contract Manufacturer And Client (Impact Weightage – 20% )  

4.1.4 Lean Manufacturing And Agility (Impact Weightage – 15%) 22

4.2 Restraints 23

4.2.1 Supply Chain Complexity And Issues Of Control Of 3rd Parties May Hamper The Market (Impact Weightage – 45%) 23

4.2.2 Standardization And Interoperability Issues ( Impact Weightage – 35% ) 24

4.2.3 Growing Cost Of Noncompliance And Counterfeited Medicines Will Reduce The Market ( Impact Weightage -20% ) 25

4.3 Opportunities 26

4.4 Challenges 27


5.1 Porter’s Five Force Analysis 28

5.1.1 Introduction 28

5.1.2 Threat From A New Entrant 29

5.1.3 Bargaining Power Of Buyer 30

5.1.4 Bargaining Power Of Supplier 31

5.1.5 Threat From Substitute 31

5.1.6 Intensity Of Competitive Rivalry 32


Send An Enquiry @


About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India